RT Journal Article
T1 Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC® Natural Adjuvant against Aspergillosis
A1 Pérez-Cantero, Alba
A1 Serrano López, Dolores Remedios
A1 Navarro Rodríguez, Patricia
A1 Schätzlein, Andreas G.
A1 Uchegbu, Ijeoma F.
A1 Torrado Durán, Juan José
A1 Capilla, Javier
AB Invasive pulmonary aspergillosis represents one of the most serious fungal infections among immunocompromised patients. In this study, we aimed to analyze the in vivo e_cacy of prophylactic oral amphotericin B (AMB) encapsulated in modified chitosan-nanoparticles (Nanomerics’ Molecular Envelope Technology (MET)) supplemented with a standardized extract of cultured Lentinula edodes mycelia (AHCC®) in a murine model of pulmonary aspergillosis. We determined fungal burden and survival of mice and additionally, we carried out a cytokine analysis in an attempt to understand the immunomodulation of the extract. Our results evidenced equivalent e_cacy between orally administered AMB-MET and the intravenous liposomal AMB marketed formulation. Addition of the AHCC® supplement significantly improved e_cacy in terms of burden reduction and survival increase of both oral and intravenous AMB therapies compared to the untreated control group. Moreover, a protective e_ect of the extract was observed in terms of weight loss. Regarding the cytokine profiles, the Th1 immune response was stimulated in treated animals when compared to the control group. This response was marked by an enhancement in the MCP-1, GM-CSF, VEGF, RANTES and IL-17 levels and a decrease in the IL-6, a biomarker related to the severity of the infection.
PB MDPI
SN 1999-4923
YR 2019
FD 2019-09-03
LK https://hdl.handle.net/20.500.14352/12753
UL https://hdl.handle.net/20.500.14352/12753
LA eng
NO Universidad Complutense de Madrid
NO UCL School of Pharmacy, University of London
NO Generalitat de Catalunya
DS Docta Complutense
RD 14 may 2025